Core Insights - The report highlights changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies. Group 1: Recent Increases in Holdings - VITASOY INT'L (00345) saw an increase of 0.09%, bringing its latest holding percentage to 3.75% [1] - 恒生科技ETF (03032) increased by 0.04%, with a current holding of 18.49% [1] - 永升服务 (01995) experienced a rise of 0.01%, now holding 4.57% [1] - 南方东西精选 (03441) had the largest increase over five days at 18.46%, reaching 41.03% [4] - 喜相逢集团 (02473) increased by 10.04%, with a holding of 45.14% [4] - 兆易创新 (03986) rose by 4.95%, now at 6.65% [4] Group 2: Recent Decreases in Holdings - 南方恒生科技 (03033) experienced the largest decrease of -0.14%, with a current holding of 68.87% [2] - 医渡科技 (02158) decreased by -0.03%, now at 22.59% [2] - 盈富基金 (02800) saw a reduction of -0.02%, with a holding of 3.49% [2] - 山东墨龙 (00568) had a five-day decrease of -1.30%, now at 53.56% [5] - 亿华通 (02402) decreased by -1.00%, with a holding of 27.49% [5] - 国富氢能 (02582) saw a reduction of -0.90%, now at 20.14% [5] Group 3: Long-term Trends in Holdings - Over a 20-day period, 喜相逢集团 (02473) had the highest increase of 42.45%, reaching 45.14% [6] - 南方东西精选 (03441) increased by 27.31%, now at 41.03% [6] - 钧达股份 (02865) rose by 15.74%, with a holding of 64.80% [6] - 天齐锂业 (09696) experienced a significant decrease of -6.48%, now at 31.50% [6] - 金风科技 (02208) decreased by -5.88%, with a holding of 42.49% [6]

Core Insights - Yidu Tech has launched the "Yidu Smart Cycle" clinical evidence AI tool, currently in the internal testing phase, aimed at meeting the real needs of clinical doctors and medical researchers [1][2] - The AI tool is built on a foundation of over 30,000 authoritative sources selected from more than 40,000 guidelines and integrates over 5 million high-quality research outcomes from 30 million documents [1] - The tool has been validated through clinical trials with over 100,000 real clinical cases, achieving decision-making levels close to that of chief physicians [1] Company Developments - The internal testing phase involves frontline doctors with real practice backgrounds to provide feedback for optimizing the product's clinical utility [2] - There are plans to launch an app version to reach a broader audience of doctors [2] - The product aims to address the growing importance of evidence-based medicine in clinical decision-making and seeks to fill a market gap in high-quality clinical evidence AI in China [2]

Core Insights - Yidu Tech has launched the "Yidu Smart Evidence" clinical evidence AI tool, currently in internal testing, aimed at meeting the real needs of clinicians and researchers [1][2] - The AI tool is built on a foundation of over 30,000 authoritative sources selected from more than 40,000 guidelines and integrates over 5 million high-quality research outcomes from 30 million documents [1] - The tool has been validated with over 100,000 real clinical cases and has shown decision-making capabilities close to that of chief physicians in authoritative clinical evaluations [1] Group 1 - The "Yidu Smart Evidence" tool focuses on transforming medical documents into computable atomic knowledge, accurately identifying clinical needs and providing evidence-based references while minimizing AI hallucinations [1] - The internal testing involves frontline clinicians to optimize the product's clinical practicality, with plans to launch an app version to reach more doctors [2] - The increasing importance of evidence-based medicine in clinical decision-making positions "Yidu Smart Evidence" as a localized innovation comparable to OpenEvidence, with potential for a sustainable business model in the high-quality clinical evidence AI market in China [2]

Core Viewpoint - The company, Yidu Tech (02158), demonstrates confidence in its development and industry prospects through continuous share buybacks and product innovation in the AI healthcare sector [1]. Group 1: Share Buyback Activity - On February 24, Yidu Tech announced a share buyback of 720,000 shares at approximately HKD 5.96 per share, totaling nearly HKD 4.3 million [1]. - Since January 26, the company has completed 17 buybacks, with a cumulative expenditure exceeding HKD 72 million, reflecting a strong commitment to shareholder value [1]. Group 2: Product Development - Yidu Tech's clinical evidence-based AI tool, "Yidu Zhixun," has entered internal testing, aimed at meeting the real needs of clinical doctors and medical researchers [1]. - The internal testing involves frontline doctors with real practice backgrounds to optimize the product's clinical practicality based on genuine feedback [1]. - The previously developed "Doctor Copilot" has been utilized nearly 1,000 times daily in a single hospital, covering about 70% of clinical healthcare personnel, indicating strong product adoption [1]. Group 3: Industry Context - The AI healthcare industry is driven by both policy and technology, with a national directive aiming for full coverage of intelligent diagnostic assistance in secondary hospitals by 2030 [1]. - Clinical evidence-based tools are becoming essential in the industry, positioning Yidu Tech favorably as it continues to innovate and solidify its competitive edge in the AI healthcare sector [1].

Core Viewpoint - The company, Yidu Tech (02158), demonstrates confidence in its development and industry prospects through continuous share buybacks and product innovation in the AI healthcare sector [1]. Group 1: Share Buyback Activity - On February 24, Yidu Tech announced a share buyback of 720,000 shares at approximately HKD 5.96 per share, totaling nearly HKD 4.3 million [1]. - Since January 26, the company has completed 17 buybacks, with a cumulative expenditure exceeding HKD 72 million, reflecting a strong commitment to shareholder value [1]. Group 2: Product Development - Yidu Tech's clinical evidence-based AI tool, "Yidu Zhixun," has entered internal testing, aimed at clinical doctors and medical researchers, focusing on real-world clinical and research needs [1]. - The internal testing involves frontline doctors with real practice backgrounds to optimize the product's clinical usability based on actual feedback [1]. - The previously developed "Doctor Copilot" tool has been utilized nearly 1,000 times daily in a single hospital, covering about 70% of clinical healthcare personnel, indicating strong product adoption [1]. Group 3: Industry Context - The AI healthcare industry is driven by both policy and technology, with a joint issuance from eight national departments outlining plans for full coverage of intelligent diagnostic assistance in secondary hospitals by 2030 [1]. - Clinical evidence-based tools are becoming essential in the industry, positioning Yidu Tech favorably as it continues to innovate and reinforce its competitive edge in the AI healthcare sector [1].

Group 1 - The company, Yidu Tech (02158.HK), announced a share buyback on February 24, spending HKD 4.289 million to repurchase 720,000 shares [1]

智通财经APP讯，医渡科技(02158)发布公告，于2026年2月24日斥资428.9万港元回购72万股。 ...

医渡科技(02158)发布公告，于2026年2月24日斥资428.9万港元回购72万股。 ...

| 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2026年2月20日 | | 1,050,409,790 | | 22,107,300 | | 1,072,517,090 | | 1). 購回股份 (股份被持作庫存股份) | | | -720,000 | 0.0685 % | 720,000 HKD | | 5.96 | | 購回股份 (股份被持作 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 重新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年2月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前 ...